drugset / Trial / NCT00902161

A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)

NCT00902161

Phase 1 Completed 22 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

This study will assess the effect of combined treatment with MK0893 plus propranolol versus placebo plus propranolol on hypoglycemia.

Timeline

Start
2009-05
Primary completion
2009-10
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-0893 Small molecule 1000 mg
Background Propranolol Small molecule 80 mg